Varubi FDA Approval History
FDA Approved: Yes (First approved September 1, 2015)
Brand name: Varubi
Generic name: rolapitant
Dosage form: Tablets and Injection
Company: Tesaro Inc.
Treatment for: Nausea/Vomiting, Chemotherapy Induced
Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.
Development Timeline for Varubi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.